Copaxone

DRUG8 trials

Conditions

Acute Decompensated Heart FailureBasal Cell CarcinomaCutaneous Squamous Cell CarcinomaCytokine StormGlaucoma, Angle-closure, Primary, AcuteHeart FailureInflammatory ResponseLow Bone Density

Phase 1

A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors

NCT03982212

University of Kansas Medical CenterBasal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma

Start: 2019-07-26End: 2024-07-31Target: 10Updated: 2023-05-19

Phase 2

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)

CompletedNCT00451204

University of California, Los AngelesRelapsing Remitting Multiple Sclerosis

Start: 2007-03-31End: 2014-07-31Updated: 2016-06-16

Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure

CompletedNCT06003972

Hadassah Medical OrganizationAcute Decompensated Heart Failure, Cytokine Storm, Heart Failure +1

Start: 2021-01-04End: 2023-03-12Updated: 2023-08-22

Phase 3

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

CompletedNCT00099502

BayerMultiple Sclerosis, Relapsing-Remitting

Start: 2003-11-30End: 2007-08-31Updated: 2008-12-19

Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure

NCT01936129

Singapore Eye Research InstituteGlaucoma, Angle-closure, Primary, Acute

Start: 2010-09-30Target: 196Updated: 2013-09-06

Phase 4

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI

CompletedNCT00176592

University of Medicine and Dentistry of New JerseyMultiple Sclerosis

Start: 2003-01-31End: 2007-01-31Updated: 2021-11-16

Unknown Phase

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

CompletedNCT00490906

Nancy Hammond, MDLow Bone Density, Multiple Sclerosis

Start: 2007-06-30End: 2012-12-31Updated: 2014-01-22

Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)

CompletedNCT00937157

University at BuffaloMultiple Sclerosis

Start: 2007-09-30End: 2011-04-30Updated: 2021-03-19

Translational Medicine Communications2023-02-271 citations

MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis

Neurology2017-07-2023 citations

Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.

2015-11-29142 citations

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

2009-09-02273 citations